Methods for treating and preventing prostate cancer bone metastases
Methods for treating a subject having a prostate cancer bone metastasis are disclosed. Methods for prophylactically treating a subject at risk of developing a prostate cancer bone metastasis are also disclosed. The methods for treating a subject having, or at risk of developing, a prostate cancer bone metastasis may include administering a prostatic acid phosphatase inhibiting agent to the subject. The methods for treating a subject having, or at risk of developing, a prostate cancer bone metastasis may also include administering a phosphonic acid to the subject. Further, the phosphonic acid may include a benzylaminophosphonic acid, such as [phenyl[(phenylmethyl)amino]methyl]-phosphonic acid).
1. A method for treating a subject having an osteoblastic prostate cancer bone metastasis, comprising:
administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a benzylaminophosphonic acid, a biologically active derivative of a benzylaminophosphonic acid, or a pharmaceutically acceptable salt, ester, solvate, isomer, or complex thereof.
2. The method of claim 1 , wherein the benzylaminophosphonic acid is [phenyl[(phenylmethyl)amino]methyl]-phosphonic acid.
3. The method of claim 1 , wherein the pharmaceutical composition is an inhibitor of prostatic acid phosphatase (PAP).
4. The method of claim 1 , wherein the pharmaceutical composition reduces a pathological effect or symptom of the prostate cancer bone metastasis.
5. The method of claim 4 , wherein the pathological effect or symptom of the osteoblastic prostate cancer bone metastasis is selected from at least one of bone pain, a bone fracture, spinal cord compression, and an increased blood calcium level.
6. The method of claim 1 , wherein the subject has at least one of stage III prostate cancer, stage IV prostate cancer, and castration-resistant prostate cancer.
7. The method of claim 1 , further comprising:
identifying the subject having the osteoblastic prostate cancer bone metastasis.
8. The method of claim 1 , wherein the subject is a human or a mammal.
9. A method for prophylactically treating a subject at risk of developing an osteoblastic prostate cancer bone metastasis, comprising:
administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a benzylaminophosphonic acid, a biologically active derivative of a benzylaminophosphonic acid, or a pharmaceutically acceptable salt, ester, solvate, isomer, or complex thereof.
10. The method of claim 9 , wherein the benzylaminophosphonic acid is [phenyl[(phenylmethyl)amino]methyl]-phosphonic acid.
11. The method of claim 9 , wherein the pharmaceutical composition is an inhibitor of prostatic acid phosphatase (PAP).
12. The method of claim 9 , wherein the pharmaceutical composition reduces the risk of developing the prostate cancer bone metastasis.
13. The method of claim 9 , further comprising:
identifying a subject having prostate cancer or at risk of developing an osteoblastic prostate cancer bone metastasis.
14. The method of claim 9 , wherein the subject has at least one of stage III prostate cancer, stage IV prostate cancer, and castration-resistant prostate cancer.
15. The method of claim 9 , wherein the subject is a human or a mammal.
16. A method for treating a pathological effect or symptom of an osteoblastic prostate cancer bone metastasis in a subject, comprising:
administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a prostatic acid phosphatase (PAP) inhibiting agent, wherein the PAP inhibiting agent is selected from the group consisting of a benzylaminophosphonic acid, a biologically active derivative of a benzylaminophosphonic acid, and a pharmaceutically acceptable salt, ester, solvate, isomer, and complex thereof.
17. The method of claim 16 , wherein the PAP inhibiting agent is [phenyl[(phenylmethyl)amino]methyl]-phosphonic acid.